Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Change in Cash: 2015-2024

Historic Change in Cash for Apellis Pharmaceuticals (APLS) over the last 10 years, with Dec 2024 value amounting to $60.3 million.

  • Apellis Pharmaceuticals' Change in Cash rose 196.47% to $109.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.4 million, marking a year-over-year increase of 249.04%. This contributed to the annual value of $60.3 million for FY2024, which is 130.04% up from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Change in Cash stood at $60.3 million for FY2024, which was up 130.04% from -$200.8 million recorded in FY2023.
  • In the past 5 years, Apellis Pharmaceuticals' Change in Cash ranged from a high of $215.1 million in FY2020 and a low of -$200.8 million during FY2023.
  • Its 3-year average for Change in Cash is -$76.4 million, with a median of -$88.7 million in 2022.
  • In the last 5 years, Apellis Pharmaceuticals' Change in Cash tumbled by 218.70% in 2022 and then soared by 130.04% in 2024.
  • Apellis Pharmaceuticals' Change in Cash (Yearly) stood at $215.1 million in 2020, then plummeted by 65.26% to $74.7 million in 2021, then slumped by 218.70% to -$88.7 million in 2022, then plummeted by 126.40% to -$200.8 million in 2023, then surged by 130.04% to $60.3 million in 2024.